HUM:NYSEHumana Inc. Analysis

Humana’s stock is trading at $304, comfortably above its 20‑day ($262), 50‑day ($215) and 200‑day ($243) moving averages, reflecting a strong recent price advance. The 14‑day RSI of 80 and a bullish MACD histogram (+3.5) signal an overbought condition, while volume is on an upward trend, suggesting the rally is still supported by buying interest. However, the 30‑day volatility of 46% and a beta below 0.7 point to heightened price swings and limited correlation with broader market moves.
Fundamentally, revenue surged 23.5% YoY to $39.65 B and forward EPS is projected at $15.46, cutting the forward P/E to ~19.7 versus a trailing P/E of 32.5, yet the DCF fair value of $458 implies the current price is materially overvalued. Margins remain thin (gross 14%, operating 4.7%, profit 0.8%) and net debt is offset by a cash pile, supporting a dividend yield of 1.16% with a 38% payout ratio, which appears sustainable. Analyst consensus is a “hold,” and recent earnings missed consensus despite top‑line growth, adding a note of caution to the near‑term outlook.